other things being equal, organic growth via paying customers is the time-honored way of avoiding the pathologies you mention.
in this model speculative capital is only required in the very early stages. a company either reaches a symbiotic relation with its clients or not. the burden is primarily on intrinsic aspects of what the startup venture delivers and how much this resonates in its sector.
the VC model is basically turbo-charging this process. though it is risk capital and not lending, it creates an implicit, arbitrarily sized liability that need not have much to do with the underlying value proposition. it removes the organic cashlow constraint via a faustian bargain.
the "beauty" of it is that you can't have both models in the same economy. the set of ideas that are ripe for exploration at an given era are what they are. if some people pursue them while being on steroids this means there is no room for people to explore them in a less toxic way
in this model speculative capital is only required in the very early stages. a company either reaches a symbiotic relation with its clients or not. the burden is primarily on intrinsic aspects of what the startup venture delivers and how much this resonates in its sector.
the VC model is basically turbo-charging this process. though it is risk capital and not lending, it creates an implicit, arbitrarily sized liability that need not have much to do with the underlying value proposition. it removes the organic cashlow constraint via a faustian bargain.
the "beauty" of it is that you can't have both models in the same economy. the set of ideas that are ripe for exploration at an given era are what they are. if some people pursue them while being on steroids this means there is no room for people to explore them in a less toxic way